Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz + Stavudine + Didanosine in ART-Naive HIV
NCT00002225Phase 2Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Safety of Efavirenz in Combination With Stavudine and Didanosine and Effectiveness of Efavirenz in Combination With Stavudine and Didanosine. Status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002225.